A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

Merck & Co's FDA approval for Keytruda in advanced liver cancer looks secure, after an Asian clinical trial found that the cancer immunotherapy improved survival in these patients. Keytruda ...

Studies suggest that two of every five pregnant people experience chronic (long-lasting) hives, mainly during the third trimester. Changes in hormones are the primary cause during pregnancy, although ...